Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

TumoR microEnvIronment Normalization FOR enhanCed photodynamic thErapy

Project description

Enhancing photodynamic therapy with anti-fibrotic treatment

Photodynamic therapy (PDT) is a cancer treatment that uses a photosensitising drug activated by specific light wavelengths to selectively kill tumour cells. Its effectiveness, however, is often limited by the tumour microenvironment (TME), which can be stiffened by the formation of dense fibrous tissue or other physical and biological barriers that hinder drug delivery. With the support of the Marie Skłodowska-Curie Actions programme, the REINFORCE project will investigate whether combining PDT with approved anti-fibrotic drugs that remodel and normalise the TME can improve therapeutic outcomes in breast cancer. Using in vitro studies, in vivo murine models and mathematical modelling, the research team aims to optimise combination therapies that overcome resistance factors and enhance PDT efficiency.

Objective

The progression of cancer is closely associated with alterations in the mechano-cellular phenotype and in the structure and mechanical properties of the tumor microenvironment (TME) in a complex and not well-understood manner. Desmoplasia, a tumour-associated fibrotic reaction, is responsible for tumor stiffening, poses a major barrier to effective drug delivery. Although novel therapeutic strategies that target cancer cells are emerging, their efficacy varies due to intra- and inter-patient variability as well as tumor heterogeneity. Notably, photodynamic therapy (PDT) is gaining prominence as a compelling alternative. This two-stage treatment harnesses both light energy and a specialized drug (photosensitizer, PS) to target cancer cells upon activation by a specific wavelength of light. However, the effectiveness of PDT is greatly compromised by various resistance factors originating from the complex TME. These factors can present several biological barriers, including desmoplasia. In this project, we propose the use of TME normalization treatment with approved anti-fibrotic drugs in combination with PDT. We aim to test the hypothesis that the combination of anti-fibrotic drugs that remodel and normalize the TME with PDT can increase the PDT efficiency. The specific research objectives are focused on breast cancer (BC) and includes in vitro study of the effect of different components of PDT treatment on BC cells, in vivo study of the effectiveness of the combination of PDT with anti-fibrotic treatment in murine BC models and mathematic modelling to optimize the combination therapies. In the proposed project, the fellow will acquire scientific and complementary skills according to his personalized career development plan and through advanced training, international and inter-sectoral mobility will reach a position of professional maturity in research.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-PF-01

See all projects funded under this call

Coordinator

EUROPEAN UNIVERSITY - CYPRUS LTD
Net EU contribution
€ 164 328,00
Address
DIOGENES STREET 6 ENGOMI
22006 Nicosia
Cyprus
Region
Κύπρος Κύπρος Κύπρος
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (2)